Effect of Selenium on Incidence and Severity of Mucositis during Radiotherapy in Patients with Head and Neck Cancer

Elahe Laali\textsuperscript{a} / Soheila Manifar\textsuperscript{b} / Ali Kazemian\textsuperscript{c} / Zahra Jahangard-Rafsanjani\textsuperscript{d} / Kheirollah Gholami\textsuperscript{e}

Purpose: Oral mucositis (OM) is the most frequent side effect of radiation. Selenium deficiency leads to increased levels of free oxygen radicals and the selenium level tends to fall during radiotherapy. Hence, in this double-blind randomised controlled clinical trial, the effect of selenium was assessed in patients receiving radiation.

Materials and Methods: Patients with head and neck cancer who were candidates to receive radiation were instructed to use selenium 200 mcg tablets twice daily. The grade of OM was evaluated by the World Health Organization (WHO) grading system on a weekly basis. The selenium level was measured at baseline and at the end of the radiation.

Results: Seventy-one patients with head and neck cancer (37 in the selenium group, 34 in the placebo group) were enrolled in the study. The cumulative incidence of OM (grade 1–4) was 97.3% in the selenium and 100% in placebo group (p value: 0.79), and difference in the mean serum selenium level at the end of radiation was not statistically significant between the two groups (p value 0.24).

Conclusion: Selenium supplementation does not appear to affect the selenium level as well as the severity and duration of OM. It is supposed that higher doses may be effective in the prevention of RT-mucositis. This trial was registered in the Iranian Registry of Clinical Trials accessible at www.irct.ir (ID No. IRCT2014072718612N1)

Key words: selenium, oral mucositis, head and neck cancer, radiation, concurrent chemotherapy, prevention

Head and neck cancer is the third most common cancer in the world. Treatment of head and neck cancer involves multidisciplinary strategies including surgery, radiotherapy (RT), chemotherapy, targeted therapy or a combination of the above.\textsuperscript{13} RT is one of the core treatment modalities in the head and neck cancer. While production of reactive oxygen species (ROS) increases the antitumor process through radiation,\textsuperscript{4} normal cells also experience dysfunction and damage.\textsuperscript{26} Oral mucositis (OM), a painful inflammation and ulceration of the mucous membranes, is the most frequent side effect of radiation with an incidence of 80–97%.\textsuperscript{7,16,37} OM develops in four phases. First, free radicals released by the mucosa cause inflammation. Second, epithelial turnover declines; erythema and atrophy start in this stage and microtraumas lead to ulceration. Third, pseudomembrane formation and microbial colonisation may cause infection. Finally, recovery and healing will be achieved in the fourth phase.\textsuperscript{25}

In general, clinical features are diagnostic in OM. Indeed, several criteria are used for grading OM. The WHO has classified OM into five grades of anatomical change from no change (stage 0) to ulceration with necrosis (stage 4) based on objective and subjective variables of OM.\textsuperscript{27} Cumulative doses of radiation have a crucial effect on the severity and onset of OM. At cumulative doses of 10 Gy, erythema appears and patients feel a burning sensation. After about 2 weeks when the patient has received 30 Gy of radiation, unbearable complications such as pain and
inability to chew and eat appear.\textsuperscript{32,34} Grade 3 and 4 (G3, G4), which are considered a severe form of OM, lead to unplanned interruption in the treatment, worsening the patient’s quality of life and survival.\textsuperscript{3} Therefore, prevention of severe OM is important in the cancer treatment process.

Studies have evaluated several preventive and symptom-managing agents.\textsuperscript{7,14,29,30} Although some of them have significantly improved the symptoms of radiation OM, none of them has been approved by caregivers and international guidelines.\textsuperscript{19}

Since inflammation and ROS formation have important roles in OM pathogenesis, antioxidants and anti-inflammatory agents have been evaluated for prevention of OM in several studies with some benefits.\textsuperscript{12,22} Selenium, an essential trace element, plays an important role as a cofactor in glutathione peroxidase, an endogenous antioxidative system.\textsuperscript{20} Hence, selenium deficiency leads to increase levels of free oxygen radicals by diminishing the enzymatic activity of glutathione peroxidase and the selenium level tends to fall during radiotherapy.\textsuperscript{8,21} Additionally, adverse effects, interruption of cancer treatment and quality of life are related to the selenium level. Furthermore, studies have shown that selenium can reduce the grade and incidence of radiation and chemotherapy OM.\textsuperscript{12,24,27,28}

Hence, in this double-blind randomised controlled clinical trial, the effect of selenium supplementation on the incidence and severity of OM was assessed in patients receiving radiotherapy, with or without chemotherapy.

**MATERIALS AND METHODS**

This double-blind placebo-controlled randomised clinical trial was conducted in Imam Khomeini Hospital Complex, Tehran, Iran, from February 2015 to March 2017. Patients with head and neck cancer who were scheduled to receive radiation as part of their cancer treatment were enrolled in this study. This trial was registered in the Iranian Registry of Clinical Trials available at www.irct.ir (ID No. IRCT2014072718612N1).

**Ethics**

The study was approved by the Ethics Committee of Tehran University of Medical Sciences and written informed consent was obtained from all participants.

**Sample Size**

The study sample size was calculated 84 patients (42 participants in each study group) assuming a 30% decrease in the incidence of OM according to the result of a pilot study, with a statistical power 80% and a two-sided significance level of 5%.\textsuperscript{5}

**Patient Selection**

Patients with head and neck cancer who were due to receive radiation on at least two-thirds of the oral cavity were included in the study. Patients aged 18–85 years with a normal renal function (creatinine clearance > 60 ml/min) and an acceptable performance status (Karnofsky performance...
The assessments were performed by an assigned oral medicine specialist (SM) and one author (EL) who were both blind to groups.

Table 1  Baseline characteristics of the patients

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Selenium group n = 37</th>
<th>Placebo group n = 34</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>25 (67.9)</td>
<td>25 (73.5)</td>
</tr>
<tr>
<td>Age, year</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>52.14</td>
<td>54.74</td>
</tr>
<tr>
<td>Median</td>
<td>51</td>
<td>57.50</td>
</tr>
<tr>
<td>Minimum–Maximum</td>
<td>22–81</td>
<td>18–81</td>
</tr>
<tr>
<td>Cancer type, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SCC</td>
<td>25 (67.6)</td>
<td>26 (76.5)</td>
</tr>
<tr>
<td>NPC</td>
<td>4 (10.8)</td>
<td>4 (11.8)</td>
</tr>
<tr>
<td>ADC</td>
<td>4 (10.8)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Melanoma</td>
<td>1 (2.4)</td>
<td>1 (2.9)</td>
</tr>
<tr>
<td>Neuroblastoma</td>
<td>1 (2.4)</td>
<td>1 (2.9)</td>
</tr>
<tr>
<td>Metastasis of other cancer</td>
<td>2 (5.4)</td>
<td>2 (5.9)</td>
</tr>
<tr>
<td>Total radiation dose, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤6000 Gy</td>
<td>19 (51.3)</td>
<td>15 (44.1)</td>
</tr>
<tr>
<td>&gt;6000 Gy</td>
<td>18 (48.6)</td>
<td>19 (55.9)</td>
</tr>
<tr>
<td>Concurrent chemotherapy, n (%)</td>
<td>18 (48.6)</td>
<td>16 (47.1)</td>
</tr>
</tbody>
</table>

SCC, Squamous cell carcinomas; NPC, nasopharyngeal carcinoma; ADC, adenocarcinoma.

The oral status of each patient was evaluated on the first day and then on a weekly basis until radiotherapy finished, and then after one month. Objective or subjective symptoms were checked by these two criteria to determine the incidence, severity and duration of OM in the participants.

Chemotherapy Subgroup
The grade of neutropenia and renal failure was evaluated based on the NCI CTCAE ver. 4.03. A creatinine level increase of > 0.3 mg/dL or 1.5–2.0 mg/dL above baseline was considered as renal failure and a neutrophil count decrease to 1000–500 mm³ was considered as grade 3 of this toxicity.

Selenium Level Monitoring
Serum samples were obtained from both groups at baseline and at the end of radiotherapy. Selenium supplementation was discontinued at least 24 h before sampling. The serum samples were stored in two separate microtubes at −80°C until selenium assay was done. The selenium level was determined using the graphite furnace atomic absorption spectrometry (Atomic Absorption, Agilent, Germany, selenium level reported in mcg/L).

Statistical Evaluation
The SPSS software was used to analyse the data and p values less than 0.05 were considered statistically significant.

RESULTS
Initially 84 patients were recruited for this investigation, of whom 13 patients dropped out after initiation of radiotherapy. Consequently, there were 37 and 34 patients in the
Almost all patients experienced some degree of OM. The cumulative incidence of OM (grade 1–4) was not significantly different between the two groups (97.3% in selenium and 100% in the placebo group, p value: 0.79, Fig 2).

These patients were followed-up and analysed (Fig 1). The baseline characteristics of the patients were similar in both study groups. The patients’ data are summarised in Table 1.
Severe OM (grade 3, 4) was seen in 25 and 20 patients in the selenium and placebo group, respectively. According to severe OM development, the log rank analysis showed no difference between the two groups (p value 0.78). However, the Kaplan-Meier graph (Fig 3) showed a difference in the severity of OM between the two groups in the third week (p value 0.78). Meanwhile, linear-by-linear association analysis showed a statistically significant difference in severe OM incidence between two groups in week 3 (p value 0.017; 42% in the placebo group and 9.8% in the selenium group).

The mean duration of OM (grade 1–4) was not different between the two groups (46.97 ± 20.26 days in the selenium and 50.44 ± 17.56 days in the placebo group, p value 0.27).

Other evaluated OM variables such as the onset and recovery time of OM and duration of severe OM are presented in Table 2.

Evaluation of the concurrent chemoradiation subgroup (n = 18 in the selenium group and n = 16 in the placebo group) showed no statistically significant differences in the incidence of other adverse effects related to chemoradiation such as neutropenia (2 patients in selenium and 3 patients in placebo group with grade 3 neutropenia) and renal failure (7 patients in selenium group compare to 3 patients in placebo group) between the two groups.

Regarding the serum selenium level, alterations of selenium level were not statistically significant different between the two groups (rise in the selenium level: 17.30 ± 36.48 mcg/L in the selenium and 7.15 ± 34.92 mcg/L in the placebo group, p value 0.50). Moreover, there was no statistically significant difference in the mean serum selenium level at the end of radiation between the two groups (p value 0.24). The data of the selenium level are shown in Table 3.

Interestingly, based on the selenium level before radiation, developing severe OM was statistically significant postponed in patients who had selenium levels ≥ 65 mcg/L (p value 0.04).

**DISCUSSION**

Radiotherapy, as a modality of head and neck cancer treatment, causes many side effects such as severe OM, leading to radiation interruption, treatment cessation and reduced quality of life. Proinflammatory cytokines generated by DNA damage result in injuries and tissue destruction. There are many inconclusive studies on the prevention of OM in cancerous patients. However, oral care and non-pharmacological mouth washes such as normal saline and also supplementations like oral zinc and vitamin E are suggested in guidelines.

In this study, we evaluated the prophylactic effect of selenium supplementation on the incidence and severity of OM. Our results demonstrated that administration of selenium had no statistically significant effect on the incidence, duration and severity of radiation OM. However, according to cell culture analyses, selenium acts as a normal cell radio-protectant and high concentrations of sodium selenite in endothelial cells decrease the effects of radiation and

---

**Table 2** Effect of selenium in OM (Mean ± SD)

<table>
<thead>
<tr>
<th>Variable</th>
<th>Selenium group</th>
<th>Placebo group</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duration of OM (day) Grade 1–4</td>
<td>46.97 ± 20.26</td>
<td>50.44 ± 17.56</td>
<td>0.27</td>
</tr>
<tr>
<td>Duration of severe OM (day) Grade 3, 4</td>
<td>10.97 ± 11.49</td>
<td>14.00 ± 13.67</td>
<td>0.34</td>
</tr>
<tr>
<td>Onset of OM (week)</td>
<td>1.61 ± 0.83</td>
<td>1.70 ± 1.05</td>
<td>0.31</td>
</tr>
<tr>
<td>Recovery (day after radiation completion)</td>
<td>8.37 ± 11.39</td>
<td>8.88 ± 11.09</td>
<td>0.80</td>
</tr>
</tbody>
</table>

**Table 3** Serum selenium level (mean ± SD (mcg/L))

<table>
<thead>
<tr>
<th>Group</th>
<th>Selenium group</th>
<th>Placebo group</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Selenium level Before radiation</td>
<td>79.49 ± 25.63</td>
<td>85.38 ± 30.63</td>
<td>0.35</td>
</tr>
<tr>
<td>Selenium level After radiation</td>
<td>97.42 ± 29.21</td>
<td>93.32 ± 33.26</td>
<td>0.50</td>
</tr>
<tr>
<td>Selenium level alterations</td>
<td>17.30 ± 36.48</td>
<td>7.15 ± 34.92</td>
<td>0.24</td>
</tr>
</tbody>
</table>
highlight the possible normal cell protective effect of seleni-
num in radiation.31,33

According to this survey, there was no statistically significa-
cant rise in the plasma concentration of selenium during the
study. Therefore, ineffectiveness of selenium in reducing ra-
diation OM might be due to the insufficient selenium con-
centration in target cells. Hence, the evaluated dose of se-
lenium in this study (400 mcg) may not have been sufficient
to increase the level of selenium in patients receiving radia-
tion. Lack of adherence may contribute to this finding be-
cause we checked the adherence by only self-report. These
findings are similar to the results of a study by Kiremidjian
that showed no statistically significant rise in the selenium
level following the oral intake of 200 μg selenium in head
and neck cancer patients.15 However, some studies have
shown that supplementation with recommended dietary al-
allowance of selenium (400 mcg) causes a statistically sig-
ficant rise in other situations. Jahangard performed a ran-
domised controlled trial (RCT) on patients who underwent
allogeneic haematopoietic stem cell transplantation (HSCT)
and showed that the incidence of severe OM decreased fol-
lowing an increase in the selenium level although selenium
was administered for 14 days in that study. However, stud-
ies have shown that selenium can decrease other radiation
side effects such as diarrhoea and dysphagia in the head
and neck, cervical and uterine cancer.5,12,24

The role of the cumulative radiation dose in starting, pro-
genosis and ulceration of OM was evaluated in a review
study in 2012. The results showed that OM became severe
after receiving 20 Gy, which was about week 3 of treat-
ment.32 The results of our study showed that the onset of
OM was similar in both groups. However, in week 3 of ra-
diation, selenium could decrease incidence of severe OM.
Therefore, it can be concluded that if the dose of selenium
is increased concurrently with increasing the radiation cu-
mulative dose, severe OM may be prevented.

According to our findings, lower levels of selenium had a
negative impact on developing severe OM, as patients with
selenium levels below 65 mcg/L before radiation developed
OM earlier. It can be hypothesised that correction of the
selenium level before starting treatment may be a key point.

Nephropathy and bone marrow suppression are common
cisplatin toxicities in chemotherapy regimen and the protec-
tive role of selenium in the reduction of these side effects has
been shown in some studies.9,11 Cisplatin, as a radiosensi-
tiser, is administrated at lower doses compared to the che-
motherapy regimen.1,10 In this study, renal failure and grade
3 neutropenia occurred in a small group of patients with no
statistically significant difference between the two groups.

Limitation

Oral selenium supplementation adherence might affect the
outcome interpretation.

As a strength of this study, it was the first double-blind,
randomised, controlled study to maximise its internal valid-
ity. Moreover, using an oral cavity specialist enhanced the
accuracy of the results.

CONCLUSION

In conclusion, selenium supplementation at a dose of 400
mcg per day during radiation has no effects on the selenium
level or the incidence and severity of OM. We believe that higher doses or other routes of administration
may be effective in the prevention of radiation OM.

Acknowledgements

We express our gratitude to the staff of radiotherapy ward
and central laboratory of Imam Khomeini hospital. This re-
search received no specific grant from any funding agency
in the public, commercial or not-for-profit sectors.

REFERENCES

1. Al-Sarraf M, Pajak TF, Marcial VA, Mowry P, Cooper JS, Stetz J, et al. Con-
current radiotherapy and chemotherapy with cisplatin in inoperable squa-
59:259–265.

NCCN task force report: prevention and management of mucositis in can-

3. Bese NS, Hendry J, Jeremic B. Effects of prolongation of overall treat-
ment time due to unplanned interruptions during radiotherapy of different
tumor sites and practical methods for compensation. Int J Radiat Oncol


lenium as radioprotector in head and neck cancer patients – first clini-

et al. Limited effects of selenium substitution in the prevention of radia-
tion-associated toxicities, results of a randomized study in head and

sitis in head and neck cancer patients treated with radiotherapy and
systemic therapies: literature review and consensus statements. Crit Rev
Oncol Hematol 2016;100:147–166.


induced nephrotoxicity: a double-blind controlled randomized clinical trial.

10. Greven K, Winter K, Underhill K, Fontenesci J, Cooper J, Burke T. Prelimi-
nary analysis of RTOG 9708: adjuvant postoperative radiotherapy com-
bined with cisplatin/paclitaxel chemotherapy after surgery for patients
with high-risk endometrial cancer. Int J Radiat Oncol Biol Phys 2004;59:
168–173.

tive role of selenium on the toxicity of cisplatin-contained chemo-
therapy regimen in cancer patients. Biol Trace Element Res 1997;56:
331–341.

12. Jahangard-Rafsanjani Z, Gholami K, Hadjibabae M, Shamshiri A, Alamog-
mucositis in patients undergoing hematopoietic SCT: a randomized clini-


prophylaxis of radiation-induced oral mucositis in head and neck cancers:
a double-blind placebo-controlled randomized clinical trial. Eur J Cancer

15. Kiremidjian-Schumacher L, Roy M, Glickman R, Schneider K, Rothstein S,
Cooper J, et al. Selenium and immunocompetence in patients with head


